Amifostine as a Protector against Cisplatin-induced Toxicity in Nude Mice

REFERENCES

• Peters GJ, van der Wilt CL, Gyergyay F, et al. Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil. J Radiat Oncol Biol Phys 1992; 22: 785–9.
   PubMed Web of Science ®Google Scholar
• Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cis-platin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–12.
   PubMed Web of Science ®Google Scholar
• Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cy-toprotection with amifostine in concurrent radiochemother-apy for head and neck cancer. Ann Oncol 1998; 9: 471–3.
   PubMed Web of Science ®Google Scholar
• Treskes M, Nijtmans LG, Fichtinger-Schepman AMJ, van der Vijgh WJF. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Phar-macol 1992; 9: 1013–101.
   Google Scholar
• Wennerberg J, Biorklund A, Trope C. The effect of cisplatin and fluorouracil on xenografted human squamous cell car-cinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1988; 114: 162–7.
   Google Scholar
• Johnsson A, Kjellén E, Wennerberg J, Pero R. Metoclopramide as a modulator of cisplatin. Effects on pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissue. Anti-Can-cer Drugs 1996; 7: 483–98.
   Google Scholar
• Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJF. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992; 52: 2257–60.
   Google Scholar
• Fichtner I, Lemm M, Becker M, Berthold F. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharma-cology of cytotoxic drugs in human xenotransplanted neurob-lastomas. Anti-Cancer Drugs 1997; 8: 174–781.
   PubMed Web of Science ®Google Scholar
• Twentyman PR. Modification by WR 2721 of the response to chemotherapy of tumors and normal tissue in the mouse. Br J Cancer 1983; 47: 57–63.
   PubMed Web of Science ®Google Scholar
• Korst AEC, Boven E, van der Sterre MLT, Fichtinger-Schep-man AMJ, van der Vijgh WJF. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. Eur J Cancer 1998; 34: 412–6.
   Google Scholar
• Osieka R, Houchens DP, Goldin A, Johnson RK. Chemother-apy of human colon cancer xenografts in athymic nude mice. Cancer 1977; 40: 2640–50.
   PubMed Web of Science ®Google Scholar
• Berman R, Steel GG. Induced and inherent resistance to alkylating agents in human small cell bronchial carcinoma xenografts. Br J Cancer 1984; 49: 431–6.
   PubMed Web of Science ®Google Scholar
• Begg AC. Analysis of growth delay data: potential pitfalls. Br J Cancer 1980; 41 (Suppl): 93–7.
   Google Scholar
• Johnsson A, Olsson C, Andersson H, Cavallin-Stahl E. Eval-uation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 1994; 17: 142–50.
   Google Scholar
• Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, en Engelse L. Immunocytochemical detection of interaction products of cis-diammindichloroplatinum(B) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) with DNA in rodent tissues. Cancer Res 1987; 47: 6719–25.
   Google Scholar
• Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E. Pharmacokinetics and tissue distribution in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 1995; 37: 23–31.
   Google Scholar
• Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1998; 23: 2–17.
   Web of Science ®Google Scholar
• Steiger E, Oram-Smith J, Miller E, Kuo L, Vars HM. Effects of nutrition on tumor growth and tolerance to chemotherapy. J Surg Res 1975; 18: 455–61.
   PubMed Web of Science ®Google Scholar
• Daly JM, Reynolds HM, Rowlands BJ, Dudrick SJ, Copeland EM. Tumor growth in experimental animals. Nutritional manipulation and chemotherapeutic response in the rat. Ann Surg 1980; 191: 316–22.
   Google Scholar
• Shaw LM, Bonner HS, Brown DQ. Metabolic pathways of WR-2721 (ethyol, amifostine) in balb/c mouse. Drug Metab Dispos 1994; 22: 895–902.
   Google Scholar
• Yuhas JM, Cub o F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57–64.
   PubMedGoogle Scholar
• Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kid-ney with special emphasis on high dose. Cancer Chemother Pharmacol 1988; 21: 163–7.
   Google Scholar
• Pinzani V, Bressolle F, Haug U, Galtier M, Blayac JP, Balmes P. Cisplatin-induced renal toxicity and toxicity-modu-lating strategies: a review. Cancer Chemother Pharmacol 1994; 35: 1–9.
   PubMed Web of Science ®Google Scholar
• Johnsson A, Hoglund P, Grubb A, Cavallin-Stahl E. Cis-platin pharmacokinetics and pharmacodynamics in patients with squamous cell carcinoma in the head/neck or oesopha-gus. Cancer Chemother Pharmacol 1996; 39: 25–33.
   Google Scholar